Impact of Solubility Enhancement Methods on the Dissolution Rate of Valsartan Sachet

Authors

Anjam H. Abdalla, Department of Pharmaceutics, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, IraqFollow
Anoosh B. Hagop, Hawler Medical UniversityFollow
Dina A. Boya, Hawler Medical University

Corresponding Author

Anjam H. Abdalla

Authors ORCID

0000-0002-0676-3186

Document Type

Research Article

Abstract

The oral drug delivery is the most generally used route of administration that has been explored for the delivery of drugs through various pharmaceutical products. Solubility of drug plays critical role in achieving the optimum therapeutic levels of the drug in blood and thus bioavailability. There are many drugs of various therapeutic categories fall in Biopharmaceutics Classification System Classes II and IV as they lack solubility. For all these drugs, dissolution is the big issue for the absorption process. Valsartan is an effective antihypertensive agent and it can be used for the treatment of hypertension in most cases. The objective of this study is to prepare Valsartan as an oral sachet which can be used as an alternative dosage form after improvement of drug solubility using solubilizing agents such as sodium lauryl sulfate and tween 80. Three different formulas of Valsartan sachet were prepared by conventional technique of wet granulation method named conventional formula (Fc), sodium lauryl sulfate formula (Fs), and tween 80 formula (Ft) then compared with the available marketed product of Valsartan tablet (Fd) as a reference. The preformulations studies were conducted to exclude drug excipients interaction. Evaluation was performed in terms of weight variation, dose content uniformity, and drug release study using dissolution test apparatus. Fourier Transforms Infrared Spectroscopy reveals no drug excipient interaction and the drug release profile for Fs and Ft formulas within 30 min was 100.16% and 104.16%, respectively, while for Fc only 57.55% of the drug was released. This difference in the release profile was statistically significant (P < 0.05) between Fs and Ft with Fc, but a non- significant difference (P > 0.05) was observed between Fs and Ft with the marketed Valsartan tablet (Fd). The results support the possibility of using the prepared formulas Fs and Ft as a Valsartan sachet for the oral administration alternative to conventional Valsartan tablets Fd.

Keywords

Poor oral solubility, Wet granulation method, Valsartan, Sachet

How to Cite This Article

Abdalla, Anjam H.; Hagop, Anoosh B.; and Boya, Dina A. (2021) "Impact of Solubility Enhancement Methods on the Dissolution Rate of Valsartan Sachet," Polytechnic Journal: Vol. 11: Iss. 1, Article 13.
DOI: https://doi.org/10.25156/ptj.v11n1y2021.pp63-69

References

Alhmoud, H., N. E. Ibrahim, E. El-Hallous and Surfactants Solubility. 2014. Concentration and the other formulations effects on the drug release rate from a controlled release matrix. Afr. J. Pharm. Pharmacol. 8(13): 364-371.

Alkhamis, K. A., H. Allaboun and W. Y. Al-Momani. 2003. Study of the solubilization of gliclazide by aqueous micellar solutions. J. Pharm. Sci. 92(4): 839-846.

Aulton, M. E. 2000. Pharmaceutics the Science of Dosage form Design. 3rd ed. Churchill Livingstone, New York. p.25-27. Balamuralidhara, V., S. A. Sreenivas, H. V. Gangadhara and T. M. Pramodkumar. 2009. Investigation on the effect of different disintegrants on the orodispersible tablets of rabeprazole. Asian J. Sci. Res. 4: 12-19.

Bharti, V. P., V. R. Attal, A. V. Munde, A. S. Birajdar and S. Bais. 2015. Strategies to enhance solubility and dissolution of a poorly water soluble drug. J. Innov. Pharm. Biol. Sci. 2(4): 482-494.

Dalmora, M. E., S. L. Dalmora and A. G. Oliveira. 2001. Inclusion complex of piroxicam with b-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect. Int. J. Pharm. 222: 45-55.

El-Badry, M. and M. Fathy. 2006. Enhancement of dissolution and permeation rates of meloxicam by formation of its freeze dried solid dispersion in polyvinyl pyrrolidine K-30. Drug Dev. Ind. Pharm. 32(2): 141-142.

Faruki, Z. M., Rishikesh, E. Razzaque and M. A. Bhuiyan. 2013. Improvement of solubility of badly water soluble drug (ibuprofen) by using surfactants and carriers. Int. J. Pharm. Sci. Res. 4(4): 1569-1574.

Flesch, G., P. Muller and P. Lloyd. 1997. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist. Eur. J. Clin. Pharmacol. 52(2): 115-120.

Gilman, A. G., T. W. Rall., A. S. Nies and P. Taylor. 1990. The Pharmacological Basis of Therapeutics. 8th ed., Vol. 2. McGrawHill, New York. p50-64.

Kawabataa, Y., K. Wadab, M. Nakatanib and S. Yamadaa. 2011. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm. 420(1): 1-10.

Khan, F., R. T. Lohiya and M. J. Umekar. 2010. Development of UV spectrophotometric method for the simultaneous estimation of meloxicam and paracetamol in tablet by simultaneous equation, absorbance ratio and absorbance correction method. Int. J. ChemTech. Res. 2(3): 1586-1591.

Lawrence, M. J. and G. D. Rees. 2000. Microemulsions based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45(1): 89-121.

Lobenberg, R. and G. L. Amidon. 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system: New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50(1): 3-12.

Mbah, C. J. 2006. Solubilization of valsartan by aqueous glycerol, polyethylene glycol and micellar solutions. Pharm. J. 61: 322-324.

Meera, C. A. B. Singh, Sayyad and S. D. Sawant. 2010. Review on various techniques of solubility enhancement of poorly soluble drugs with special emphasis on solid dispersion. J. Pharm. Res. 3(10): 2494-2501.

Moffat, A. C. 2011. Clarke’s Analysis of Drugs and Poisons. Pharmaceutcal Press, London, United Kingdom.

Nayak, B. S., S. R. Mishra and H. Roy. 2018. Valsartan fast dissolving tablets: Formulation and in vitro characterization. J. Chem. Pharm. Res. 10(3): 182-189.

Pedersen, B. L., A. Mullertz, H. Brondsted and H. C. Kristenson. 2000. A comparision of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm. Res. 17(7): 891-894.

Pradhan, K. K. and U. S. Mishra. 2015. Development and validation of a stability indicating RP-HPLC method for the determination of valsartan. Int. J. Pharm. Pharm. Sci. 7(8): 57-61.

Rabasco, A. M., J. M. Ginesh, M. F. Arevalo and M. A. Holgado. 2002. Dissolution rate of diazepam from polyethylene glycol 6000 solid dispersions. Int. J. Pharm. 67: 201-206.

Rong, L. 2008. Water Insoluble Drug-formulation. 2nd ed. CRC Press, New York. p1-4.

Rowe, R. C., P. J. Sheskey and S. C. Owen. 2009. Handbook of Pharmaceutical Ecipients. 6th ed. Pharmaceutical Press, American Pharmacists Association, London, United Kingdom.

Takeuchi, H., S. Tanimura, S. Y. Nagira, H. Yamamoto and Y. Kawashina. 2005. Tableting of solid dispersion particles consisiting of indomathacin and porous silica particles. Chem. Pharm. Bull. 53(5): 487-491.

Usha, B. S., Y. I. Muzib, D. Bhikshapathi and R. Sravani. 2015. Enhancement of solubility and oral bioavailability of poorly soluble drug valsartan by novel solid self emulsifying drug delivery system. Int. J. Drug Deliv. 7: 13-26.

USP-30 NF-25. 2007. United State Pharmacopoeial Convention. Electronic Version.

Publication Date

6-30-2021